The "Global Viral Inactivation Market Analysis 2019" report has been added to ResearchAndMarkets.com's offering.

The Viral Inactivation market is expected to reach $1,209.17 million by 2026 growing at a CAGR of 14.2% from 2018 to 2026.

Factors such as increasing government support for pharmaceutical and biotechnology industries, an increase in the number of drug launches & approvals and rising investment in the life sciences sector are driving the market growth. Though, high cost of biologics and biosimilar products development & manufacturing restrain the market growth.

Based on the product, Kits and reagents are expected to have a lucrative growth during the forecast period due to their continuous usage by pharmaceutical and biopharmaceutical companies. With an increase in the number of pharmaceutical and biopharmaceutical companies and the rise in R&D spending for the purpose of new drug development, the usage of kits and reagents has increased tremendously.

Key Questions Answered in this Report:

The key vendors mentioned are Merck KGAA, Cerus Corporation, Thermo Fisher Scientific Inc., Sartorius AG, Danaher Corporation, Texcell, Inc., Parker Hannifin Corporation, Sanofi SA, SGS SA, Invitrogen Corp., General Electric Co., Rad Source Technologies, Qiagen NV, ZeptoMetrix Corp., MockV Solutions, Vironova AB, Viral Inactivated Plasma Systems SA, and BioReliance.

Key Questions Answered in this Report:

Key Topics Covered:

1 Market Synopsis

2 Research Outline

2.1 Research Snapshot

2.2 Research Methodology

2.3 Research Sources

2.3.1 Primary Research Sources

2.3.2 Secondary Research Sources

3 Market Dynamics

3.1 Drivers

3.2 Restraints

4 Market Environment

4.1 Bargaining power of suppliers

4.2 Bargaining power of buyers

4.3 Threat of substitutes

4.4 Threat of new entrants

4.5 Competitive rivalry

5 Global Viral Inactivation Market, By Product

5.1 Introduction

5.2 Services

5.3 Viral Inactivation Systems and Accessories

5.4 Kits and Reagents

6 Global Viral Inactivation Market, By Method

6.1 Introduction

6.2 Pasteurization

6.3 Solvent Detergent Method

6.4 Other Methods

7 Global Viral Inactivation Market, By Application

7.1 Introduction

7.2 Blood and Blood Products

7.3 Tissues and Tissue Products

7.4 Vaccines and Therapeutics

7.5 Stem Cell Products

7.6 Cellular and Gene Therapy Products

8 Global Viral Inactivation Market, By End User

8.1 Introduction

8.2 Pharmaceutical and Biotechnology Companies

8.3 Academic Research Institutes

8.4 Contract Research Organizations

8.5 Blood Banks and Hospitals

9 Global Viral Inactivation Market, By Geography

9.1 Introduction

9.2 North America

9.3 Europe

9.4 Asia Pacific

9.5 South America

9.6 Middle East & Africa

10 Strategic Benchmarking

11 Vendors Landscape

11.1 Merck KGAA

11.2 Cerus Corporation

11.3 Thermo Fisher Scientific Inc.

11.4 Sartorius AG

11.5 Danaher Corporation

11.6 Texcell, Inc.

11.7 Parker Hannifin Corporation

11.8 Sanofi SA

11.9 SGS SA

11.10 Invitrogen Corp.

11.11 General Electric Co.

11.12 Rad Source Technologies

11.13 Qiagen NV

11.14 ZeptoMetrix Corp.

11.15 MockV Solutions

11.16 Vironova AB

11.17 Viral Inactivated Plasma Systems SA

11.18 BioReliance

For more information about this report visit https://www.researchandmarkets.com/r/m0wcqb

View source version on businesswire.com: https://www.businesswire.com/news/home/20200204005900/en/

Contacts

ResearchAndMarkets.comLaura Wood, Senior Press Managerpress@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470For U.S./CAN Toll Free Call 1-800-526-8630For GMT Office Hours Call +353-1-416-8900

Follow this link:
Global Viral Inactivation Market Analysis 2016 to 2026 - Market Expected to Reach $1,209.17 Million by 2026 - ResearchAndMarkets.com - Yahoo Finance